MEDICAL MARIJUANA

Zynerba Pharmaceuticals anticipates data in late 2019 for its phase 3 cannabinoid drug



Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive Investors’ Christine Corrado at the BIO Investor Forum in San Francisco.

Zynerba is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs.

source

Leave a Reply

Your email address will not be published. Required fields are marked *